Peripheral & central neuropathic pain in adults which includes diabetic peripheral neuropathy & post-herpetic neuralgia. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Generalised anxiety disorder (GAD) in adults. Management of fibromyalgia.
Adult 150-600 mg/day given in 2 or 3 divided doses. Neuropathic pain Initially 150 mg/day given as 2 or 3 divided doses. May be increased to 300 mg/day after an interval of 3-7 days based on individual patient response & tolerability. Max dose: 600 mg/day after an additional 7-day interval, if needed. Epilepsy Initially 150 mg/day given as 2 or 3 divided doses. May be increased to 300 mg/day after a wk based on individual patient response & tolerability. Max dose: 600 mg/day may be achieved after an additional wk. GAD 150-600 mg/day given as 2 or 3 divided doses. Initially 150 mg/day. May be increased to 300 mg/day after 1 wk based on individual patient response & tolerability. Following an additional wk, dose may be increased to 450 mg/day. Max dose: 600 mg/day may be achieved after an additional wk. Management of fibromyalgia 300-450 mg daily. Initially 150 mg daily (75 mg bid). May be increased to 300 mg daily (150 mg bid) w/in 1 wk based on efficacy & tolerability. Max dose: 450 mg daily (225 mg bid). Renal impairment CrCl ≥60 mL/min Initially 150 mg/day. Max: 600 mg/day Dose regimen: Bid or tid; CrCl ≥30 to <60 mL/min Initially 75 mg/day. Max: 300 mg/day. Dose regimen: Bid or tid; CrCl ≥15 to <30 mL/min Initially 25-50 mg/day. Max: 150 mg/day. Dose regimen: Once daily or bid; CrCl <15 mL/min Initially 25 mg/day. Max: 75 mg/day. Dose regimen: Once daily. Supplementary dosage following haemodialysis Initially 25 mg/day. Max: 100 mg/day. Dose regimen: Single dose.
Discontinue use if angioedema symptoms eg, facial, perioral, or upper airway swelling occur. Diabetics. Dizziness, somnolence, loss of consciousness, confusion & mental impairment, & w/drawal symptoms may occur. Vision-related effects. Renal failure. W/drawal of concomitant antiepileptic drugs. Concomitant use w/ anti-spasticity agents in treatment of central neuropathic pain due to spinal cord injury. Monitor patients for signs of suicidal ideation & behaviours. Reduced lower GI tract function. History of substance abuse. Encephalopathy. CHF may occur in CV compromised elderly. May have minor or moderate influence on the ability to drive & use machines. Effective contraception must be used in women of childbearing potential. Pregnancy & lactation. Childn <12 yr & adolescents 12-17 yr. Elderly >65 yr.
May potentiate effects of ethanol & lorazepam. Resp failure & coma may occur w/ other CNS depressants. Additive in the impairment of cognitive & gross motor function caused by oxycodone.
Sign Out
